Study material: Astrazeneca-Krebsmedikament und reißt AstraZeneca-Aktie in de Tiefe

AstraZeneca has made a mistake with an important helper function.

The drug “Datopotamab Deruxtecan” under investigation was a risk for treatment by the US FDA in a single week. The action fell in the form of 4.6 Percent.

The drug has not significantly improved the medical care of patients with non-small lung function, leaving AstraZeneca working in the Montagabend.

De AstraZeneca-rutscht im Nachgang der Meldung an der Londoner Börse zeitweise een 4.81 Prozent auf 121.00 Pfund ab.

By Helena Smolak

LONDON (Dow Jones)